NGNE

Neurogene's stock was impacted by several events in the past six months. The stock soared after NGN-401 received FDA Breakthrough Therapy designation. The company reported its full-year 2025 financial results and provided updates on its clinical programs, including the progress of NGN-401, and announced that the Embolden™ registrational trial for NGN-401 was fully enrolled. Fintel increased Neurogene's price target. Neurogene announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. Neurogene announced upcoming presentations on the therapeutic rationale for ICV delivery in CNS-targeted gene therapy.